BLAINJECTIONINJECTABLEPriority Review
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
262
Data completeness
5/8 — Partial
Priority Review
IMFINZI (durvalumab) by AstraZeneca is programmed death ligand-1 antagonists [moa]. First approved in 2017.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMFINZI (durvalumab) is a monoclonal antibody that blocks Programmed Death Ligand-1 (PD-L1), unleashing the immune system to attack cancer cells. It is administered intravenously and is approved for multiple cancer indications including unresectable Stage III non-small cell lung cancer (NSCLC) and other solid tumors. The drug represents a key checkpoint inhibitor in the immuno-oncology landscape.
$0.025BPart D
PeakProduct is at peak lifecycle stage with moderate Part D claims; commercial teams are likely focused on market penetration and indication expansion rather than launch activities.
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (262)
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Started Jan 2027
50 enrolled
Extensive-stage Small-cell Lung Cancer
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Started Jan 2027
430 enrolled
Limited Stage Small-Cell Lung Cancer
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)
Started Dec 2026
564 enrolled
Small Cell Lung Cancer
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
Started Dec 2026
33 enrolled
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Started Nov 2026
140 enrolled
GastricEsophagogastric Junction
Worked on IMFINZI at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.